{"id":475576,"date":"2020-03-23T13:32:01","date_gmt":"2020-03-23T13:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=475576"},"modified":"2020-03-23T13:32:01","modified_gmt":"2020-03-23T13:32:01","slug":"aneurysmal-subarachnoid-hemorrhage-asah-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/aneurysmal-subarachnoid-hemorrhage-asah-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_475576.html","title":{"rendered":"Aneurysmal Subarachnoid Hemorrhage (aSAH) Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight"},"content":{"rendered":"
\"Aneurysmal<\/a><\/div>\n

 <\/p>\n

DelveInsight has launched a new report on Aneurysmal Subarachnoid Hemorrhage (aSAH) Market Insights, Epidemiology and Market Forecast-2030<\/strong><\/p>\n

DelveInsight’s ‘Aneurysmal Subarachnoid Hemorrhage (aSAH) – Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of aSAH in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.<\/p>\n

The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of aSAH from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.<\/p>\n

Aneurysmal Subarachnoid Hemorrhage (aSAH) is a serious condition that not just affects the brain, but multiple other organ systems as well. Despite a steady reduction of mortality from acute SAH in recent years, from over half to approximately one-third, this entity is still associated with considerable morbidity and mortality. Aneurysmal subarachnoid hemorrhage (aSAH) is a worldwide health burden with high fatality and permanent disability rates. These aneurysms, located at the branching point of proximal intracranial arteries, are not uncommon and found in about 2% of the adult population (and even more frequently in those with a family history of aSAH or polycystic kidney disease).<\/div>\n
 <\/div>\n
\"\"<\/div>\n
 <\/div>\n
 <\/div>\n
 <\/div>\n
Request for :-<\/strong> Aneurysmal Subarachnoid Hemorrhage (aSAH)  free sample page<\/a><\/div>\n
 <\/div>\n
 <\/div>\n
Aneurysmal Subarachnoid Hemorrhage Epidemiology<\/strong><\/p>\n

The aSAH epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.<\/p>\n

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [Total incident population, Sex-specific incidence, Grade-wise incidence and Diagnosed cases] scenario in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.<\/p>\n

According to DelveInsight, total incident population of aSAH in 7 major markets were about 84,208 in 2016.<\/p>\n

 <\/p>\n

Report Key facts :- <\/strong><\/p>\n<\/div>\n

1. According to the study conducted by Yamaki et al., titled “Delayed Ischemic Neurologic Deficit after Aneurysmal Subarachnoid Hemorrhage,” the delayed ischemic neurologic deficit (DIND) affects up to 30% of patients with aSAH. Conversely, it is the main preventable cause of poor outcomes in those patients.<\/div>\n
 <\/div>\n
2. As per the study conducted by Kongable et al. titled “Gender-related differences in aneurysmal subarachnoid hemorrhage,” female gender is a recognized risk factor for the occurrence of aneurysmal subarachnoid hemorrhage. In the study, it was observed that female harbored aneurysms of the internal carotid artery more frequently than male patients (36.8% vs. 18.0%) and often had multiple aneurysms (32.4% vs. 17.6%).<\/p>\n

3. The study conducted by Tamimi et al. titled “A Review of Delayed Ischemic Neurologic Deficit Following Aneurysmal Subarachnoid Hemorrhage: Historical Overview, Current Treatment, and Pathophysiology” estimated the incidence of aneurysmal subarachnoid hemorrhage (aSAH) to be 6–8 per 100,000 annually, with a peak incidence in the fifth decade. Delayed ischemic neurologic deficit (DIND; also referred to as clinical\/symptomatic vasospasm or delayed cerebral ischemia) is a severe and poorly understood complication of aSAH, occurring in 20–40% of patients.<\/p>\n

 <\/p>\n

“As per the study by Davis et al. titled “Incidence, epidemiology, and treatment of aneurysmal subarachnoid hemorrhage in 12 mid-west communities,” 6–16 per 100,000 people in the United States is likely to develop aSAH, and the incidence was double in a Minnesota population between 1945 and 1974”<\/em><\/strong><\/p>\n<\/div>\n

 <\/div>\n
Key companies working on eSAH that are given below- <\/strong><\/div>\n
 1.  Evgen Pharmaceutical Co. <\/div>\n
 2. Actelion Pharmaceutical Co. <\/div>\n
 <\/div>\n
Name of drugs covered are given below- <\/strong><\/div>\n
1. SFX-01<\/div>\n
2. Clazosentan<\/div>\n
 <\/div>\n
Table of Contents<\/a><\/div>\n
 <\/div>\n
\n

1. Key Insights<\/p>\n

2. Aneurysmal Subarachnoid Hemorrhage (aSAH) Market Overview at a Glance<\/p>\n

2.1. Market Share (%) Distribution of aSAH in 2017<\/p>\n

2.2. Market Share (%) Distribution of aSAH in 2027<\/p>\n

3. Disease Background and Overview: Aneurysmal Subarachnoid Hemorrhage<\/p>\n

3.1. Introduction<\/p>\n

3.2. Symptoms<\/p>\n

3.3. Etiology and Risk Factors<\/p>\n

3.4. Grading<\/p>\n

3.5. Pathophysiology<\/p>\n

3.6. Diagnosis<\/p>\n

3.7. Biomarkers<\/p>\n

3.8. Management<\/p>\n

4. Epidemiology and Patient Population<\/p>\n

4.1. Key Findings<\/p>\n

5. 7MM Total Incident Patient Population of Aneurysmal subarachnoid hemorrhage<\/p>\n

6. Country Wise-Epidemiology of Aneurysmal subarachnoid hemorrhage<\/p>\n

7. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

8. Unmet Needs<\/p>\n

9. Marketed drugs<\/p>\n

10. Emerging Drugs<\/p>\n

11. Aneurysmal Subarachnoid Hemorrhage (aSAH): 7 Major Market Analysis<\/p>\n

12. Market Drivers<\/p>\n

13. Market Barriers<\/p>\n

14. Appendix<\/p>\n

14.1. Report Methodology<\/p>\n

15. DelveInsight Capabilities<\/p>\n

16. Disclaimer<\/p>\n

17. About <\/strong>DelveInsight<\/a><\/p>\n<\/div>\n

 <\/div>\n
\n

Report Benefits:- <\/strong><\/p>\n

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving aSAH market.<\/p>\n

• Organize sales and marketing efforts by identifying the best opportunities for aSAH market.<\/p>\n

• To understand the future market competition in the aSAH market.<\/p>\n

 <\/p>\n

Related Reports :- <\/strong><\/p>\n<\/div>\n

1. Aneurysmal Subarachnoid Hemorrhage (SAH) – Pipeline Insights, 2020<\/a><\/div>\n
2. Aneurysmal Subarachnoid Hemorrhage (SAH) – Epidemiology Forecast to 2030<\/a><\/div>\n
 <\/div>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

  DelveInsight has launched a new report on Aneurysmal Subarachnoid Hemorrhage (aSAH) Market Insights, Epidemiology and Market Forecast-2030 DelveInsight’s ‘Aneurysmal Subarachnoid Hemorrhage (aSAH) – Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[400,406,420],"tags":[],"class_list":["post-475576","post","type-post","status-publish","format-standard","hentry","category-Agriculture-Farming","category-Pharmaceuticals-Biotech","category-Science"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/475576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=475576"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/475576\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=475576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=475576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=475576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}